We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
3 Promising Genomics Stocks to Add to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
The global genomics market is projected to reach $99.26 billion by 2034, growing at a 12.66% CAGR.
Illumina, uniQure and 10x Genomics are advancing sequencing, gene therapies and single-cell technologies.
All three stocks carry a Zacks Rank #2 (Buy), with QURE and TXG posting notable share-price gains.
An updated edition of the Sept. 8, 2026, article.
Genomics is the study of genomes, which encompass an organism’s entire set of deoxyribonucleic acid (DNA). Recent scientific advances in this area have heightened interest from pharmaceutical and biotechnology companies seeking insight into disease biology and more effective therapeutic strategies.
Genetics and genomics differ in their scope. Genetics primarily examines individual genes, whereas genomics focuses on analyzing and characterizing an organism’s complete set of genes. Genomics provides insights into how genes function within a biological system, interact with one another and respond to environmental influences.
Insights from genomic research are increasingly being used to evaluate how patients respond to specific drugs. These findings are also driving the development of precise, more targeted treatments, contributing to the advancement of personalized medicine. As demand for innovative therapies continues to grow, genomics is poised to play an increasingly central role in the future of healthcare, despite the complexity inherent in genome-scale research.
The expanding genomics landscape has also supported the growth of synthetic biology, which applies engineering principles to biology. This emerging field involves redesigning organisms for diverse applications, including drug discovery, disease detection, enzyme engineering, gene editing and foundational research.
The rapid progress in the novel space of genomics has been fueled by steep declines in the cost, time, and effort needed to sequence an individual’s genome. Diagnostic companies are using genomic sequencing data to identify genetic variations and connect them to known diseases. In contrast, other companies apply sequencing technologies to develop solutions across healthcare and other industries.
Another major advancement in the field is the emergence of genome-editing technologies, most notably CRISPR/Cas9. Companies specializing in gene editing, such as CRISPR Therapeutics AG (CRSP - Free Report) ) and Beam Therapeutics, Inc. (BEAM - Free Report) , are exploring these tools to potentially treat or even cure diseases caused by genetic mutations. As the name implies, these technologies enable precise modifications to an organism’s DNA, allowing scientists to correct harmful defects at their source.
According to Fortune Business Insights, the global genomics market was valued at $34.23 billion in 2025 and is expected to expand from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% over the period.
Per a Grandview Research article, the global synthetic biology market size was valued at $18.9 billion in 2025 and is projected to reach $69.2 billion by 2033, at a CAGR of 17.7% from 2026 to 2033.
If you're looking to capitalize on this trend, our Genomics and Synthetic Biology screen makes it easy to identify high-potential stocks at any given time. At present, stocks such as Illumina (ILMN - Free Report) , uniQure (QURE - Free Report) and 10x Genomics (TXG - Free Report) hold potential.
Illumina is advancing human health by harnessing the potential of genomics. Illumina benefits from its leading position in the global DNA sequencing and array-based technologies markets. Its broad product portfolio supports applications across disease research, drug development, molecular diagnostics, oncology, reproductive health and agriculture.
The company serves a diverse customer base, including genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical and biotechnology companies, diagnostic laboratories and consumer genomics businesses.
On Jan. 30, 2026, Illumina acquired SomaLogic, a proteomics company, to strengthen its presence in the protein analysis market and advance its multiomics strategy. The acquisition expands Illumina's technology portfolio beyond genomics and could create additional growth opportunities through integrated genomics and proteomics solutions.
uniQure N.V. is a clinical-stage gene therapy company focused on developing one-time AAV-based treatments for rare and severe diseases. The company is advancing a focused pipeline of innovative gene therapies, with lead clinical programs targeting Huntington's disease, refractory mesial temporal lobe epilepsy, and Fabry disease.
uniQure is developing ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for Huntington's disease, using its proprietary miQURE gene-silencing platform. Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA. Ifezuntirgene inilparvovec also holds Fast Track designation from the FDA. The company has made important regulatory progress, including submitting a biologics license application to the FDA and a Marketing Authorisation Application in the United Kingdom, creating significant value if approved.
QURE currently carries a Zacks Rank #2. Its shares have gained 8.2% in a month.
10x Genomics is a life sciences technology company developing innovative tools to study complex biological systems. Its commercial portfolio comprises Single Cell and Spatial solutions. The company’s products include instruments such as Chromium, Visium CytAssist and Xenium Analyzer, along with proprietary microfluidic chips, slides, reagents and other consumables. The company also provides software to support workflows ranging from sample preparation to data analysis and visualization. Its revenues are primarily generated from instrument and consumables sales, supplemented by post-warranty service contracts.
TXG currently carries a Zacks Rank #2. Shares of the company have surged 72.6% over the past three months.
View the Zacks #1 Rank List
Image: Bigstock
3 Promising Genomics Stocks to Add to Your Portfolio Now
Key Takeaways
An updated edition of the Sept. 8, 2026, article.
Genomics is the study of genomes, which encompass an organism’s entire set of deoxyribonucleic acid (DNA). Recent scientific advances in this area have heightened interest from pharmaceutical and biotechnology companies seeking insight into disease biology and more effective therapeutic strategies.
Genetics and genomics differ in their scope. Genetics primarily examines individual genes, whereas genomics focuses on analyzing and characterizing an organism’s complete set of genes. Genomics provides insights into how genes function within a biological system, interact with one another and respond to environmental influences.
Insights from genomic research are increasingly being used to evaluate how patients respond to specific drugs. These findings are also driving the development of precise, more targeted treatments, contributing to the advancement of personalized medicine. As demand for innovative therapies continues to grow, genomics is poised to play an increasingly central role in the future of healthcare, despite the complexity inherent in genome-scale research.
The expanding genomics landscape has also supported the growth of synthetic biology, which applies engineering principles to biology. This emerging field involves redesigning organisms for diverse applications, including drug discovery, disease detection, enzyme engineering, gene editing and foundational research.
The rapid progress in the novel space of genomics has been fueled by steep declines in the cost, time, and effort needed to sequence an individual’s genome. Diagnostic companies are using genomic sequencing data to identify genetic variations and connect them to known diseases. In contrast, other companies apply sequencing technologies to develop solutions across healthcare and other industries.
Another major advancement in the field is the emergence of genome-editing technologies, most notably CRISPR/Cas9. Companies specializing in gene editing, such as CRISPR Therapeutics AG (CRSP - Free Report) ) and Beam Therapeutics, Inc. (BEAM - Free Report) , are exploring these tools to potentially treat or even cure diseases caused by genetic mutations. As the name implies, these technologies enable precise modifications to an organism’s DNA, allowing scientists to correct harmful defects at their source.
According to Fortune Business Insights, the global genomics market was valued at $34.23 billion in 2025 and is expected to expand from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% over the period.
Per a Grandview Research article, the global synthetic biology market size was valued at $18.9 billion in 2025 and is projected to reach $69.2 billion by 2033, at a CAGR of 17.7% from 2026 to 2033.
If you're looking to capitalize on this trend, our Genomics and Synthetic Biology screen makes it easy to identify high-potential stocks at any given time. At present, stocks such as Illumina (ILMN - Free Report) , uniQure (QURE - Free Report) and 10x Genomics (TXG - Free Report) hold potential.
Explore 40 cutting-edge investment themes with Zacks Thematic Investing Screens and uncover your next big opportunity.
3 Genomics Stocks to Consider
Illumina is advancing human health by harnessing the potential of genomics. Illumina benefits from its leading position in the global DNA sequencing and array-based technologies markets. Its broad product portfolio supports applications across disease research, drug development, molecular diagnostics, oncology, reproductive health and agriculture.
The company serves a diverse customer base, including genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical and biotechnology companies, diagnostic laboratories and consumer genomics businesses.
On Jan. 30, 2026, Illumina acquired SomaLogic, a proteomics company, to strengthen its presence in the protein analysis market and advance its multiomics strategy. The acquisition expands Illumina's technology portfolio beyond genomics and could create additional growth opportunities through integrated genomics and proteomics solutions.
ILMN currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
uniQure N.V. is a clinical-stage gene therapy company focused on developing one-time AAV-based treatments for rare and severe diseases. The company is advancing a focused pipeline of innovative gene therapies, with lead clinical programs targeting Huntington's disease, refractory mesial temporal lobe epilepsy, and Fabry disease.
uniQure is developing ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for Huntington's disease, using its proprietary miQURE gene-silencing platform. Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA. Ifezuntirgene inilparvovec also holds Fast Track designation from the FDA. The company has made important regulatory progress, including submitting a biologics license application to the FDA and a Marketing Authorisation Application in the United Kingdom, creating significant value if approved.
QURE currently carries a Zacks Rank #2. Its shares have gained 8.2% in a month.
10x Genomics is a life sciences technology company developing innovative tools to study complex biological systems. Its commercial portfolio comprises Single Cell and Spatial solutions. The company’s products include instruments such as Chromium, Visium CytAssist and Xenium Analyzer, along with proprietary microfluidic chips, slides, reagents and other consumables. The company also provides software to support workflows ranging from sample preparation to data analysis and visualization. Its revenues are primarily generated from instrument and consumables sales, supplemented by post-warranty service contracts.
TXG currently carries a Zacks Rank #2. Shares of the company have surged 72.6% over the past three months.